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Abstract. The effects of amrubicin (AMR) and its  active 
metabolite, amrubicinol (AMROH), on the sensitivity of 
human lung adenocarcinoma A549 cell line to hyperthermia 
at  44°C were investigated. The cell phase response as well as 
the kinetics of apoptosis and necrosis induction were also 
analyzed. The cytocidal effects of  44°C hyperthermia on A549 
cells exhibited low thermosensitivity with a  To value of 12  min. 
The slope of the survival curve in the exponential phase, 
described semilogarithmically, in  44°C hyperthermia 
combined treatment with AMROH (0.02  .tg/ml) was 
approximately parallel to  44°C hyperthermia lone. The initial 
shoulder shape portion of the survival curve from  44°C 
hyperthermia lone, indicating the repair of sublethal  thermal 
damage (SLTDR), was reduced with the sequential combined 
treatment of AMR or AMROH. Sequential treatments with 
AMR or AMROH prior to  44°C hyperthermia resulted in 
additive thermo-enhancement effect by reducing not only 
survival but was shoulder wide. Furthermore, like AMR and 
AMROH, adriamycin (ADM) and etoposide  (VP-16) are DNA 
topoisomerase II inhibitors, and the effects of these 4 agents 
on  44°C hyperthermia were compared. All 4 agents exhibited 
comparable thermo-enhancement effects. Using synchronized 
A549 cells, AMR or AMROH did not elicit cell phase 
responses, irrespective of the concentration. The induction of 
apoptosis was investigated at 48 and 72 h after  AMROH 
treatment,  44°C hyperthermia or the combined treatment, in 
which apoptosis was not significantly induced after any 
treatment. Furthermore, the incidence of necrosis was
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examined as well as  apoptosis. The incidence of necrosis at 48 
and 72  h after AMROH was 2.4 and 4.3%, respectively; after 
 44°C hyperthermia was 3.3 and 4.0%, respectively; and after 
the combined treatment  it was 10.7 and 8.7%, respectively. 
The necrosis induced after the combined treatment was circa 
3 times higher than that in either of the single treatments.
Introduction
 Amrubicin hydrochloride (AMR) is the first totally-chemically 
synthesized anthracycline derivatives  (12). and it exhibits anti-
tumor activity against human non-small cell lung, small cell 
lung and superficial bladder cancer (3-5). AMR exerts its 
 antitumor effects by inhibiting  topoisomerase II activity and 
suppressing DNA synthesis (6,7). AMR is metabolized to 
AMROH in vivo (2), and the results of our in vitro study 
using human lung cancer A549 cells evidenced that the 
cytocidal effects of AMROH were about 10 times more 
potent than those of AMR. The survival curves of A549 cells 
treated with isotoxic doses of AMR and AMROH showed the 
same profile. When cancer cells are exposed to hyperthermia, 
the cells usually acquire thermo-tolerance during heating or 
afterwards, which has been one of the problems associated 
with thermotherapy (8-10). Thermo- and  chemo-therapy, a 
 combined treatment with hyperthermia nd chemical agents, 
has been adopted as an interdisciplinary treatment strategy to 
overcome  the problems of  thermotolerance. 
  We previously reported that the lethal sensitivity in the 
simultaneous combined treatment with  42°C hyperthermia 
and adriamycin (ADM) for the initial short time was markedly 
higher but followed by reduced lethal sensitivity, the 
sequential treatment showed the tolerant lethal sensitivity (11). 
In this study, the modification of thermo-sensitivity by AMR 
or AMROH was  investigated using A549 cells in vitro. A549 
cell line originating  from human lung  adenocarcinoma was 
established by Giard et  al (12,13). Several studies have been 
conducted on the sensitivity of A549 cells to radiation and 
hyperthermia (14-17). 
  It has been clarified at the molecular level that A549 cells 
have a mutated K-ras gene (18) and the wild-type p53 gene 
(19). When DNA is damaged,  wild-type p53 protein is
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Figure 1. Cytocidal effect of AMROH  in graded concentration on survival 
of A549 cells. Ordinate: log surviving fractions (SFs) in colony forming unit. 
Abscissa: treatment periods of AMROH in hours. Symbols of the survival 
curve represent he concentration of  AMROH in open circles (0.01  1g/m1), 
closed circles (0.02  pg/m1), open triangles (0.1  pg/m1) and closed triangles 
(0.2  11g/int), respectively. Symbols with vertical bars represent means with 
standard errors obtained from three independent SFs. Symbols without a bar 
represent he standard error within the symbols.
Figure 2. Effect of  thermo-enhancement of AMR  (0.2  ps/m1) in A549 cells. 
Ordinate: log surviving  fractions (SFs) in colony forming unit. Abscissa: 
heating periods at  44°C in minutes. Open circles represent SFs of cells from 
 44°C hyperthermia alone. Open triangles represent SFs of cells treated with 
hyperthermia at  44°C for graded periods followed by AMR for 3 h. Closed 
triangles represent SFs of cells from  hyperthermia at  44°C for graded 
periods  after pre-treatment with AMR for 3 h. Symbols with vertical bars 
represent means with standard  errors obtained from three independent SFs. 
Symbols without a bar represent he standard error within the symbols.
activated by phosphorylation on signaling pathway, and the 
activated p53 exhibits antitumor effects by inducing either 
apoptosis or  G1 arrest (20-25). The ras gene was one of the 
first oncogenes discovered, and it is involved in cellular 
proliferation and differentiation (26-28), but there have not 
been any studies investigating the relationship between the 
ras gene and thermosensitivity. 
  In the present study, we analyzed the effects of AMR and 
AMROH on the thermosensitivity of A549 cells with the 
above-mentioned genetic backgrounds. We examined the 
thermo-enhancement effects of  isotoxic doses of AMR and 
AMROH on the sensitivity of A549 cells to  44°C hyperthermia 
and compared the effects of AMR and AMROH with those 
of two other DNA topoisomerase II inhibitors (ADM and 
VP-16). With regard to cell phase responses to hyperthermia, 
the survival curve for mild hyperthermia t  40°C was flat and 
responses were not appreciable for any phase (16), but the 
responses for experimental hyperthermia at  44°C showed 
marked cytotoxicity in the S phase  (30,31). 
  We conducted a study using bleomycin, a DNA synthesis 
inhibitor, and confirmed that the survival curve for syn-
chronized cells was flat regardless of drug concentration, and 
that cell phase responses were not appreciable during cell phase 
progression (30). The cell phase responses to AMR and 
AMROH have not been clarified. Therefore, we investigated 
the cell phase responses of A549 cells synchronized with
 hydroxyurea to AMR and AMROH. In murine L cells having 
wild-type p53 that show high thermosensitivity, hyper-
thermia effectively induced apoptosis (8). 
  Here, in A549 cells that have wild-type p53 gene and are 
not thermosensitive, the induction of apoptosis (32,33) and 
necrosis (34,35) was investigated following AMROH treatment 
combined sequentially with  44°C hyperthermia. The effects of 
AMR and its active metabolite, AMROH, on the sensitivity of 
A549 cells to  44°C  hyperthermia were analyzed at the kinetic 
and molecular levels.
Materials and methods
Cells and culture medium. A549, a human lung adeno-
carcinoma cell line, cultured in Eagle's minimum essential 
medium (Nissui Pharmaceutical, Tokyo, Japan) containing 
 NCTC-135 (Gibco Laboratories, Grand Island, NY, USA), 
lactalbumin hydrolysate solution (Difco Laboratories, Detroit, 
USA) and 15% newborn calf serum (Gibco) (hereinafter 
referred to as MLN-15), was used (12,13).
Chemicals,  hyperthermia and treatments. AMR or AMROH 
(Sumitomo Pharmaceuticals  Co., Ltd. Osaka, Japan) was 
dissolved in the culture medium to an appropriate final 
concentration for the treatment. The adhered cells in the flasks 
were treated with AMR  or AMROH by replacement with 6 ml 
of the AMR or AMROH solution in MLN-15 for graded
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  For cell  phase responses, A549 cells were treated with 
4 mM hydroxyurea  (HU) (Sigma Chemical, St. Louis, MO, 
USA) (36,37)  for 5 h to synchronize  them at the  G,-S border, 
and after an interval of 1-9  h, cells were treated with AMR or 
AMROH  for 4 h. Cell phase responses were also analyzed by 
the colony  formation methods.
0
Figure 3. Effect of thermo-enhancement of AMROH (0.02  µg/nil) in A549 
cells. Ordinate: log surviving fractions (SFs) in colony forming unit. 
Abscissa: heating periods at  44°C in minutes. Open circles represent SFs of 
cells from 44°C hyperthermia alone. Open triangles represent SFs of cells 
treated with  hyperthermia at 44°C for graded periods followed by  AMR011 
for 3 h. Closed triangles represent SFs of cells from  hyperthermia at  44°C 
for graded periods after pre-treatment with  AMROH for 3 h. Symbols with 
vertical bars represent means with standard errors obtained from three 
independent SFs. Symbols without a bar represent he standard error within 
the symbols.
periods. After the exposure to AMR or AMROH, the adhered 
cells were chased, gently rinsed twice and re-fed with 6 ml of 
the culture  medium. MLN-15. Thus, treated  flasks were 
incubated stationarily for visible colony formation. 
  Hyperthermia was carried out by immersion of culture 
flasks of the tightened screw tops in a temperature-regulated 
water bath (Model EPS-47, Tokyo Seisakusho Co., Tokyo, 
Japan) pre-set at 44°C. The temperature was maintained within 
the error of ±0.05°C as measured with a thermistor (Model 
 DI16-1251, Takara Thermistor Instruments Co., Yokohama, 
Japan). 
  For combined treatment with chemotherapy and  thermo-
therapy were carried out sequentially. Cells  treated  with AMR 
or AMROH for 3 h were rinsed twice with culture  medium. 
containing 3% serum, placed in MLN-15 and followed by 
44°C hyperthermia. Kinetic assessment of the sensitivity of 
A549 cells to agents and hyperthermia was carried out by the 
colony formation method and corrected based on the plating 
efficiency of the control  (i.e., 80-90%). The average colony 
multiplicity was <1.1. The  T„ value, adopted as the criterion 
of cellular thermo- or  chemo-sensitivity, represented the 
treatment period required to reduce survivals by  1/e in the 
exponentially regressing portion of the survival curves, i.e., 
the linear portions of the treatment period in survival curves 
 semilogarithmically.
 Analysis of apoptosis and necrosis. Induction of apoptosis 
was analyzed at 48 and 72 h  after treatment with 0.02  p.g/ml 
AMROH for 4 h. 44°C  hyperthermia for 35  min, or the  com-
bined treatment. Trypsinized cells were placed in MLN-15 to 
stop trypsinization, rinsed with PBS(-),  fixed overnight in 1% 
glutaraldehyde (Nacalai Tesque Inc., Kyoto, Japan), and placed 
in PBS(-). For observation, cells were stained with 0.2 mM 
 Hochst  33342;  13isbenzimide H33342 Fluorochrome, Trihydro-
chloride  (Calbiochem, Merck KGoA,  Dortnstodt, Germany) 
and were analyzed under a fluorescence microscope (Nikon 
Eclipse E600, Nikon Co.  Ltd, Tokyo, Japan). A total of 1,000 
cells were counted, and the percentage of typical apoptotic 
cells was calculated. The induction of necrosis was also 
determined after the above-described treatments. After double-
staining the cells using acridine orange (Sigma-Aldrich Co. 
St. Louis, USA) and  ethidium bromide (Nacalai Tesque Inc., 
Kyoto, Japan)  (AO/EB)  (38), cells were observed in real-time 
under a fluorescence microscope, and the percentage of typical 
necrotic cells was calculated.
 Results
 Cytotoxic effects of AMROH. A549 cells were treated with 
graded concentrations of AMROH (0.01, 0.02, 0.1 or 0.2  tig/ 
ml) for 1-10  h in order to determine its cytotoxic effects as 
shown in Fig.  1. For each concentration, the surviving 
 fraction of cells were plotted against reatment time on a 
semilogarithmic chart. All curves showed steeply a slope 
during the initial stages of treatment. At concentrations of
0.01 and 0.02  .tg/ml, the curves gradually reached aplateau 
after 4 to 6 h, and the plateau was maintained  510 h at all 
concentrations. AMROH was markedly cytotoxic during the 
early stages of treatment,  but no marked changes in 
sensitivity were seen beyond 4  h.
 Heating period  (44`C) -  survival relationships ofA549 cells. 
With regard to the thermosensitivity of A549 cells, the  T0 value 
(close required to reduce the survival by  1/e), which is the 
 reciprocal of the slope of the survival curve in the exponential 
phase, was 12  min for 44°C hyperthermia. As is the case with 
the Elkind recovery associated with low-dose radiotherapy, the 
repair of sublethal thermal damage (SLTDR), which is seen 
as a curve shoulder, was identified uring the early stages of 
hyperthermia. The Tq value, a sort of cellular capacity for 
SLTDR, was 6.5  min as shown in Fig. 2.
The effects of  AMROH on  hyperthermia. Using A549 cells, 
the thermo-enhancement effects of AMR and AMROH were 
investigated based on the survival curves drawn after 44°C 
hyperthermia and AMROH combination therapy in Figs. 2 
and 3. The survival curve of the cells performed with 44°C 
hyperthermia alone elicited a shoulder, indicating the repair 
of SLTD, whereas the curve of sequentially combined
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Table I. Comparison of thermo-enhancement by four 
topoisomerase  II inhibitors.
 44°C alone Chemical -  44°C 
 T„ Tu
Enhancement 
   ratio
1,33 
1.40 
1.33 
1.47
1.0
AMR 
AMROH 
ADM 
 VP-16
1.40 
1.40 
1.40 
1.40
1.05 
1.00 
1.05 
0.95
The  thermo-enhancement effects to  44°C  hyperthermia of 4 agents in 
DNA topoisomerase  11 inhibitor, AMR,  AMROH, ADM and VP-16, 
were compared by  T„ value. The A549 cells were treated with agent 
prepared at isotoxic dose,  AMR (2.5  iig/m1), AMROH (0.02  tg/ml), 
ADM (0.02  ps/m1) or VP-16 (2.0  µg/ml) for 3 h respectively and 
followed by hyperthermia at 44°C for 30  min in the combined 
treatment.
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treatment with AMR or AMROH was reduced. The SLTDR 
associated with short-term  hyperthermia was blocked by 
AMR or AMROH. The slope of the survival curve in the 
exponential phase for 44°C  hyperthermia and the combi-
nation therapy with AMR or AMROH were parallel, i.e. 
administration of AMR or AMROH prior to hyperthermia 
showed additive  thermo-enhancement effects. The  thermo-
enhancement effects of 4 topoisomerase II inhibitors, ADM, 
VP-16, AMR and AMROH, on 44°C hyperthermia for 30  min 
were compared as shown in Table I. The effects of 4 agents 
in isotoxic doses were comparable, markedly enhancing the 
effects of hyperthermia.
Cell phase responses to AMR and AMROH. A549 cells 
synchronized at the  G,-S border by treatment with 4 mM HU 
for 5 h were incubated for graded periods of time, and were 
further exposed to AMR and AMROH in order to analyze the 
cell phase responses as shown in Fig. 4. As a control. 
synchronized cells were incubated for graded periods of time 
and were treated with 4  mM HU for 2 h, not shown in the 
figure. Cell survival was plotted in order to compare the 
results with the standard cell-cycle phase. After a specified 
interval, synchronized A549 cells were treated with 3 graded 
concentrations of AMR or AMROH for 4 h respectively, and 
the survival curve was largely flat for all cell-cycle phases at 
all concentrations. AMR and AMROH did not elicit cell phase 
responses, irrespective of the concentration.
Effects on apoptosis induction. The  thermo-enhancement 
effects of AMROH on A549 cells were investigated based on 
the induction of apoptosis as shown in Fig. 5. After AMROH 
for 4  11, 44°C  hyperthermia for 35  min or combination therapy, 
cells were harvested at 48 and 72 h after incubation and were 
fixed with glutaraldehyde. Fixed cells were stained with  Hochst 
33342 solution, and cellular morphology was observed under a 
fluorescence microscope in order to determine the percentage 
of apoptotic cells. At 48 and 72  h after treatment with 
AMROH alone, the incidence of apoptosis was 0.9% and 
1%, respectively; circa 1.3% (at both time points) for 44°C
Figure 4. Left panel shows the  HU treatment period-survival relationship of 
cells. Right panel shows the cell phase responses to AMR or AMROH in 
gradational concentration for A549 cells  synchronized by the exposure to 
HU for 5  h. Ordinates: log surviving fractions (SFs) in colony forming unit. 
Abscissa in left panel: treatment periods with 4  mM HU in  hours. Abscissa 
 in right panel: incubation  periods at 37°C between the pre-treatment with 
 HU for 5 h and the post-treatment with AMR or AMROH for 4 h. Open 
circles, open squares and open triangles represent SFs from post-treatment 
with AMR in 0.1, 0.5 and 2.5  tig/inl, respectively. Closed circles, closed 
squares and closed triangles represent SFs from post-treatment with 
AMROH  in  0.004, 0.02 and 0.1  pg/mI, respectively. Symbols with vertical 
bars represent means with standard errors obtained from three independent 
SFs. Symbols without a bar represent he standard error within the symbols.
hyperthermia alone; and 2.4 and 1.7% for combination  therapy. 
respectively.
Effects on necrosis induction. As was the case with  apoptosis, 
the thermo-enhancement effects of AMROH on A549 cells 
were investigated in the induction of necrosis. The incidence 
of necrotic ells following AMROH  treatment, 44°C hyper-
thermia or the  combination therapy was investigated by  AO/ 
EB double staining at intervals of 48 and 72 h after treatment. 
The incidence of necrosis at 48 and 72  h after treatment with 
AMROH was  2.4 and 4.3%, respectively, after 44°C 
hyperthermia was 3.3 and 4.0%, respectively, and after 
combined treatment  i was 10.7 and 8.7%, respectively as 
shown in Fig. 6.
Discussion
In the present study, the modification of AMR and AMROH 
on the thermosensitivity of A549 cells was investigated.
 Cytotoxicity of AMROH. In our study, AMROH exhibited 
marked cytotoxic activity during the early stages. AMR and 
its active metabolite,  AMROH, are DNA topoisomerase II 
inhibitors (3,4). DNA  topoisomerase  II  is reported to be vital 
for essential biological reactions such as replication, tran-
scription and genetic recombination (39-41). In 1984, Liu  et  al 
discovered that  mAMSA  [4'-(9-acridinylamino)  methanesulfon-
in-anisidide], an  antitumor agent, inhibited topoisomerase II
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Figure 5. Kinetics of apoptosis induction at 48 or 72 h of incubation periods 
after AMROH,  44°C hyperthermia or the combined treatment. At indicated 
time, A549 cells stained with Hochst 33342 were observed under a 
fluorescent microscope. The cells of DNA fragmented nuclei with typical 
morphological features of apoptosis were counted as apoptotic cells. 
Ordinate: percentages of apoptosis in the total cells. Abscissa:  37°C 
incubation periods in hours after treatment. Columns represent  AMROH 
(0.02  µg/m1) for 4  h,  44°C hyperthermia for 35  min and the combined 
treatments in order  from the left, respectively. Incidence of  apoptosis after 
treatment with AMROH or hyperthermia alone were slightly induced in 
interval periods at 48 and 72  h. In the combined treatment, no frequency of 
apoptosis increased significantly.
in mammals (42). Therefore,  topoisomerase II inhibitors 
are effective anticancer agents because topoisomerase II 
inactivation and inhibition severely affect cell survival 
(43,44).
Effects on hyperthernzia. When A549 cells were treated with 
AMR or AMROH prior to  44'C heating in vitro, the SLTDR 
seen during the early stages of hyperthermia was inhibited. 
AMR and AMROH additively enhanced the effects of  44°C 
hyperthermia. In thermotherapy forcancer, the time required 
to achieve  10% survival  (0.1 on a survival curve) for hyper-
thermia alone was 30  min, but that for the combination 
therapy was 10  min. Comparable results were obtained in 
about one-third of the time by combining  hyperthermia with 
AMR or AMROH. The fact that combining AMR or AMROH 
cuts the duration of hyperthermia to one-third is beneficial in 
multidisciplinary anticancer therapy. We have investigated 
the ability of various chemicals to modify the effects of 
 hyperthermia using different cells at the kinetic and molecular 
levels (11,30,45-47). The effects of AMR, AMROH, ADM 
(48) and  VP-16 (49), which target DNA metabolism, on the 
thermosensitivity of A549 cells were compared. When A549 
cells were treated with isotoxic doses of AMR, AMROH,
0
48 72
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Figure 6. Kinetics  of necrosis induction at 48 or 72  h of incubation periods 
after  AMROH,  44°C  hyperthermia or the combined treatment. At indicated 
time, A549 cells by double staining with AO/EB were observed  under a 
fluorescent microscope. The rubious cells were counted as necrotic cells. 
Ordinate: percentages of necrosis in the total cells. Abscissa: 37'C incubation 
periods in hours  alter treatment. Columns represent AMROH  (0.02  1.1g/m1) 
for 4 h, 44'C  hyperthermia for 35  min and the  combined treatments in order 
 from the left. respectively.  Incidences of necrosis after  AMROH or 
hyperthermia alone were both induced slightly in interval periods at 48 and 
72 h. In these  combined  treatment, the frequency of necrosis increased 
significantly.
ADM or  VP-16 for 3 h and then sequentially subjected to 
 44°C hyperthermia for 30  min, comparable degrees of 
enhancement were noted. These findings clarify that all 
topoisomerase 11inhibitors increase the  thermosensitivity of 
A549 cells.
 Cell phase responses. In order to clarify the mechanisms of 
thermal enhancement by AMR or AMROH, we investigated 
the survival curves through cell phase progression, the cell 
phase response of A549 cells to 0.1, 0.5 and 2.5  pg/m1 of 
AMR or 0.004, 0.02 and  0.1  µg/ml of AMROH were 
analyzed. All survival curves were flat, i.e., cell phase 
responses were  not seen regardless of the concentrations of 
AMR or AMROH. We reported that bleomycin (29), which 
inhibits DNA  synthesis, was cell cycle non-specific regardless 
of concentration (30). When exposed to more than moderate 
hyperthermia  or radiation, cells are most sensitive to 
 hyperthermia during the G1-S phase and to radiation during the 
G2-M phase (50,51). There was no cell phase response to mild 
hyperthermia that could be assessed uniformly in all phases 
for thermosensitivity (30),  but with  44°C experimental
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hyperthermia, sensitivity was high during the  G,-S phase  (31). 
While various studies have been conducted to determine the 
target of hyperthermia, no conclusive evidence has been 
obtained. The reason that chemicals such as AMR in Fig. 4 
and  BLM lack cell phase responses may be due to the fact that 
they target different types of DNA damage (52-54).  Hence, 
more effective synergism may be achieved by combined 
treatment with hyperthermia nd drug  administration, as the 
mirror contrast on each cell phase response, in order to 
enhance and complement antitumor effects.
Induction of apoptosis and necrosis. The induction of apoptosis 
 following  44°C  hyperthermia or 0.02  µg/ml AMROH increased 
slightly with  time, but there was no significant increase 
 following  sequential combination therapy.  However. the 
induction of necrosis following  44°C hyperthermia increased 
with time, and there was a significant increase in the induction 
of necrosis after 4 h of AMROH exposure followed  by  44°C 
hyperthermia. p53-mediated apoptosis is thought to be cell 
cycle dependent (55,56). We reported that apoptosis was 
induced effectively by  44°C hyperthermia in  thermosensitive 
murine L cells with wild-type p53 (8). The results of the present 
study were unexpected in that the cytotoxicity of AMROH 
against A549 cells having wild-type p53 in hyperthermia was 
due to increased necrosis, not increased apoptosis. In addition, 
with A549 cells, cell phase responses were not seen. This 
suggests that AMR and AMROH directly act on DNA topoiso-
merase II without affecting the p53 cascade. AMR and 
AMROH were shown to dynamically enhance the thermo-
sensitivity of A549 cells. Thus, in multidisciplinary 
anticancer  therapy, the antitumor effects of hyperthermia can 
be improved by administering AMR or its metabolite, 
AMROH (57).
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